- Home
- CCEL vs RLYB Comparison
CCEL vs RLYB Comparison
Compare CCEL & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- RLYB
- Stock Information
- Founded
- CCEL 1989
- RLYB 2018
- Country
- CCEL United States
- RLYB United States
- Employees
- CCEL N/A
- RLYB N/A
- Industry
- CCEL Managed Health Care
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- RLYB Health Care
- Exchange
- CCEL Nasdaq
- RLYB Nasdaq
- Market Cap
- CCEL 53.9M
- RLYB 45.6M
- IPO Year
- CCEL 1997
- RLYB 2021
- Fundamental
- Price
- CCEL $5.84
- RLYB $1.09
- Analyst Decision
- CCEL
- RLYB Buy
- Analyst Count
- CCEL 0
- RLYB 6
- Target Price
- CCEL N/A
- RLYB $8.30
- AVG Volume (30 Days)
- CCEL 3.6K
- RLYB 53.4K
- Earning Date
- CCEL 10-22-2024
- RLYB 11-07-2024
- Dividend Yield
- CCEL N/A
- RLYB N/A
- EPS Growth
- CCEL N/A
- RLYB N/A
- EPS
- CCEL N/A
- RLYB N/A
- Revenue
- CCEL $31,641,636.00
- RLYB $299,000.00
- Revenue This Year
- CCEL $3.70
- RLYB N/A
- Revenue Next Year
- CCEL $10.57
- RLYB N/A
- P/E Ratio
- CCEL N/A
- RLYB N/A
- Revenue Growth
- CCEL 1.93
- RLYB N/A
- 52 Week Low
- CCEL $3.67
- RLYB $1.08
- 52 Week High
- CCEL $9.50
- RLYB $4.60
- Technical
- Relative Strength Index (RSI)
- CCEL 36.99
- RLYB 44.46
- Support Level
- CCEL $6.29
- RLYB $1.08
- Resistance Level
- CCEL $6.31
- RLYB $1.18
- Average True Range (ATR)
- CCEL 0.23
- RLYB 0.04
- MACD
- CCEL -0.03
- RLYB 0.00
- Stochastic Oscillator
- CCEL 5.09
- RLYB 10.00
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.